The first patient has been dosed in the Phase I/II clinical trial of a MTHFD1/2 inhibitor to treat advanced solid tumours, biotechnology company One-carbon Therapeutics has announced. 

TH9619, a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2. TH9619 kills cancer cells via a dual mechanism of action inhibition, while sparing healthy tissues. 

“I am pleased that our subjects now have access to next-generation investigational therapies such as TH9619,” said Dr Victor Moreno, Director of Clinical Research and Principal Investigator. 

“This study opens new possibilities for cancer treatments where options remain limited, and we look forward to continuing collaborating with One-carbon Therapeutics.” 

“TH9619 embodies our unique strategy of targeting one-carbon metabolism proteins, by killing cancer cells while sparing normal cells and bringing new hope to subjects with high unmet medical need,” added Ana Slipicevic, Chief Executive Officer of One-carbon Therapeutics. 

“We are deeply grateful to the investigators, clinical teams, our collaborators, and most importantly, the subjects who make this progress possible.” 

 

Bruno Quinney, Content Team, DDW